Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 12/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169747 | 0.86 | EZH2 (0.80) | EZH2ATML3MBTL1GLAPOLB | |
| SCHEMBL17067308 | 0.85 | EZH2 (0.74) | EZH2ATML3MBTL1GLAPOLB | |
| SCHEMBL6120930 | 0.83 | EZH2 (0.71) | EZH2TSHRATML3MBTL1GLA | |
| SCHEMBL8738667 | 0.82 | EZH2 (0.67) | EZH2ATML3MBTL1GLAPOLB | |
| SCHEMBL6120964 | 0.82 | EZH2 (1.00) | EZH2TSHRATML3MBTL1GLA | |
| SCHEMBL8738202 | 0.82 | EZH2 (0.81) | EZH2ATML3MBTL1GLAPOLB | |
| SCHEMBL8738111 | 0.82 | EZH2 (0.81) | EZH2ATML3MBTL1GLAPOLB | |
| SCHEMBL8738240 | 0.82 | EZH2 (0.81) | EZH2ATML3MBTL1GLAPOLB | |
| SCHEMBL8738313 | 0.81 | EZH2 (0.79) | EZH2ATML3MBTL1GLAPOLB | |
| SCHEMBL8738545 | 0.81 | EZH2 (0.79) | EZH2ATML3MBTL1GLAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA INC (US) | 2017-12-07 | — | — | US | disclosed |
| US-9775835-B2 | Small molecule inhibitors of viral protein interactions with human t-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| WO-2014025749-A2 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | SIRGA ADVANCED BIOPHARMA, INC. (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2012068589-A2 | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348295-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | NSUN3, TARBP1, TRDMT1 | EZH2 1862/4885NPC1 2010/4885HPGD 4588/4885 |
| US-20150190384-A1 | SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA | NSUN3, TARBP1, TRDMT1 | EZH2 2132/4885NPC1 2051/4885HPGD 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.